Search

Your search keyword '"Vaccines -- Marketing"' showing total 245 results
Start Over Descriptor "Vaccines -- Marketing"
245 results on '"Vaccines -- Marketing"'

1. Moderna announces EC granted marketing authorization for mRESVIA

Subjects
Drug approval, Vaccines -- Marketing, Marketing, Company marketing practices, Business, News, opinion and commentary, European Union. European Commission
Abstract

Moderna announced that the European Commission, EC, has granted marketing authorization for mRESVIA, an mRNA respiratory syncytial virus vaccine, to protect adults aged 60 years and older from lower respiratory [...]

Published
2024

2. Moderna announces positive CHMP opinion for marketing authorization of mRESVIA

Subjects
Vaccines -- Marketing, Marketing, Company marketing practices, Business, News, opinion and commentary
Abstract

Moderna announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of marketing authorization in the European Union for [...]

Published
2024

3. Panacea Biotec's arm launches baby diapers, wipes under 'NikoMom' brand

Subjects
Diapers -- Marketing, Vaccines -- Marketing, Company marketing practices, Business, international
Abstract

The said product has been launched on January 2, 2025 Panacea Biotec's wholly owned subsidiary -- Panacea Biotec Pharma has launched baby diapers and wipes under the brand name 'NikoMom'. [...]

Published
2025

4. Pfizer announces EC grants marketing authorization for Prevenar 20

Subjects
Pfizer Inc. -- Marketing, Bacterial pneumonia, Pneumonia, Drug approval, Vaccines -- Marketing, Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Business, News, opinion and commentary, European Union. European Commission, Prevnar (Vaccine) -- Marketing
Abstract

Pfizer announced that the European Commission, or EC, has granted marketing authorization for the company's 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name Prevenar 20, [...]

Published
2024

6. Grape Achievements

Author

Dowling, Melissa

Subjects
Biological products industry -- Marketing, Wine industry -- Marketing, Beverages -- Marketing, Vaccines -- Marketing, Wineries -- Marketing, Company marketing practices, Business, Food and beverage industries, Travel industry
Abstract

After the pandemic-driven turmoil of the previous year, 2021 proved to be decent for the wine industry. As vaccines rolled out and Covid restrictions lifted, consumers started gathering again with [...]

Published
2022

7. Study Data from University of Groningen Update Understanding of Pediatric Vaccines (The effect of the implementation of the international code of marketing of breast-milk substitutes on child mortality in Ghana and Tanzania)

Subjects
Company marketing practices, Medical research, Medicine, Experimental, Pediatrics, Infant formulas -- Marketing, Mortality -- Ghana -- Netherlands -- Tanzania, Vaccines -- Marketing
Abstract

2024 OCT 7 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Vaccine Week -- New study results on pediatric vaccines have been published. According to news originating from [...]

Published
2024

8. Cathay Cargo launches new brand campaign 'We Know How'

Subjects
Vaccines -- Marketing, Company marketing practices, Advertising, marketing and public relations
Abstract

Byline: Adgully Bureau Cathay Cargo has launched its new brand campaign, 'We Know How', showcasing the brand's strength and experience as a reliable expert in air cargo solutions. From temperature-sensitive [...]

Published
2023

9. European Commission grants full marketing authorization to Novavax's Nuvaxovid for prevention of Covid

Subjects
United States. Food and Drug Administration, Novavax Inc. -- Marketing, Biotechnology industry -- Marketing, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission, Nuvaxovid (Vaccine) -- Marketing
Abstract

Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M adjuvant, has been granted full Marketing Authorization (MA) by the European Commission in the European Union (EU) for [...]

Published
2023

10. Novavax granted full marketing authorization in Europe for Nuvaxovid

Subjects
Drug approval, Vaccines -- Marketing, Marketing, Company marketing practices, Business, News, opinion and commentary, European Union, Nuvaxovid (Vaccine) -- Marketing
Abstract

Novavax said it has been granted full marketing authorization by the European Commission in the European Union for Nuvaxovid. The vaccine is now fully authorized for use as a primary [...]

Published
2023

11. UK MHRA grants marketing authorization to SK bioscience's Covid-19 vaccine, SKYCovion

Subjects
Biological products industry -- Marketing, Independent regulatory commissions, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, Coalition for Epidemic Preparedness Innovations
Abstract

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has announced the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has [...]

Published
2023

12. EMA committee recommends full marketing authorization for Novavax's Nuvaxovid for prevention of Covid in EU

Subjects
United States. Food and Drug Administration, Novavax Inc. -- Marketing, Biotechnology industry -- Marketing, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, Nuvaxovid (Vaccine) -- Marketing
Abstract

Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M adjuvant, announced that Nuvaxovid (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary [...]

Published
2023

13. University of Queensland Reports Findings in Herpes Zoster Vaccine (Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia)

Subjects
Shingles (Disease), Medical research, Medicine, Experimental, Vaccines -- Marketing, Marketing, Company marketing practices, Advertising, marketing and public relations, University of Queensland
Abstract

2024 MAY 18 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- New research on Immunization and Public Health - Herpes Zoster Vaccine is the subject [...]

Published
2024

14. SCHUMER: AS CENTRAL NY PEDIATRICIANS FACE SHORTAGES OF NEW RSV IMMUNIZATION FOR KIDS, SENATOR CALLS FOR ACTION NOW; SCHUMER LAUNCHES TWO-PRONGED PLAN FOR FEDS AND MANUFACTURERS TO GET ALL HANDS-ON DECK TO ADDRESS SHORTAGE AND DELIVER MORE DOSES FOR SYRACUSE AND CNY PEDIATRICIANS AND FAMILIES TO COMBAT RSV

Subjects
United States. Food and Drug Administration, United States. Centers for Disease Control and Prevention, Pediatrics, Immunization, Infants, Vaccines -- Marketing, Logistics, Pediatricians, Virus diseases, Product shortage, Company marketing practices, News, opinion and commentary, Upstate Medical University, Beyfortus (Vaccine) -- Marketing
Abstract

WASHINGTON -- The following information was released by New York Senator Charles Schumer: Respiratory Syncytial Virus Infection (RSV) Can Be Serious For Young Children, But The Brand New Potentially Lifesaving [...]

Published
2024

15. EMA committee recommends marketing authorization for use of Moderna's Spikevax in children 6 months to 5 years

Subjects
Moderna Inc. -- Marketing, RNA, Vaccines -- Marketing, Marketing, Coronaviruses, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union. European Commission
Abstract

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a [...]

Published
2022

16. EMA accepts Moderna's conditional marketing authorization filing for its Omicron BA.4/BA.5 targeting bivalent Covid-19 vaccine

Subjects
Moderna Inc. -- Marketing, Biotechnology industry -- Marketing, RNA, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, Spikevax Bivalent Zero/Omicron (Vaccine) -- Marketing
Abstract

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Medicines Agency (EMA) has accepted a variation for the evaluation of a 50 ôg [...]

Published
2022

17. CHMP recommends for conversion of Pfizer & BioNTech's Comirnaty conditional marketing authorization to full marketing authorization in EU

Subjects
BioNTech SE -- Marketing, Pfizer Inc. -- Marketing, Biotechnology industry -- Marketing, Drug approval, Vaccines -- Marketing, Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission
Abstract

Pfizer Inc. and BioNTech SE announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended converting the conditional Marketing Authorization (cMA) [...]

Published
2022

18. EMA committee recommends conditional marketing authorization for Pfizer & BioNTech's Omicron BA.4/BA.5-adapted bivalent Covid-19 vaccine booster

Subjects
BioNTech SE -- Marketing, Pfizer Inc. -- Marketing, RNA, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission
Abstract

Pfizer Inc. and BioNTech SE announced a 30-ôg booster dose of their Omicron BA.4/BA.5 bivalent-adapted Covid-19 vaccine (Comirnaty Original/Omicron BA.4/BA.5 15/15 ôg) has been recommended for conditional marketing authorization (cMA) [...]

Published
2022

19. CHMP recommends expanded conditional marketing authorization to Novavax Nuvaxovid Covid-19 vaccine in EU as a booster for adults aged 18 and older

Subjects
Novavax Inc. -- Marketing, Biotechnology industry -- Marketing, Adults, Vaccines -- Marketing, Marketing, Severe acute respiratory syndrome -- Prevention, Coronaviruses, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, Nuvaxovid (Vaccine) -- Marketing
Abstract

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that Nuvaxovid (NVX-CoV2373) Covid-19 vaccine has been recommended for expanded conditional marketing authorization [...]

Published
2022

20. EMA committee recommends conditional marketing authorization to Pfizer & BioNTech's Omicron BA.1-adapted bivalent Covid-19 vaccine booster

Subjects
BioNTech SE -- Marketing, Pfizer Inc. -- Marketing, Biotechnology industry -- Marketing, RNA, Vaccines -- Marketing, Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union
Abstract

Pfizer Inc. and BioNTech SE announced a 30-ôg booster dose of their Omicron BA.1 Bivalent Covid-19 vaccine (Comirnaty Original/Omicron BA.1 15/15 ôg) has been recommended for conditional marketing authorization (cMA) [...]

Published
2022

21. EMA committee recommends authorization for use of Moderna's Omicron-targeting bivalent booster, Spikevax

Subjects
Moderna Inc. -- Marketing, Biotechnology industry -- Marketing, RNA, Vaccines -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union. European Commission
Abstract

Moderna, Inc, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a [...]

Published
2022

22. Moderna says CHMP adopts positive opinion for omicron-targeting bivalent booster

Subjects
Vaccination, Vaccines -- Marketing, Company marketing practices, Business, News, opinion and commentary
Abstract

Moderna announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization for Spikevax bivalent Original/Omicron BA.1, the company's [...]

Published
2022

23. Novavax' Nuvaxovid gets expanded marketing authorization in U.K. for ages 12-17

Subjects
Vaccination, Vaccines -- Marketing, Marketing, Severe acute respiratory syndrome, Company marketing practices, Business, News, opinion and commentary, Nuvaxovid (Vaccine) -- Marketing
Abstract

Novavax announced that the Medicines and Healthcare products Regulatory Agency in the United Kingdom has granted expanded conditional marketing authorization for Nuvaxovid COVID-19 vaccine for active immunization to prevent COVID-19 [...]

Published
2022

24. Valneva receives positive CHMP opinion for marketing authorization for VLA2001

Subjects
Vaccination, Drug approval, Vaccines -- Marketing, Marketing, Company marketing practices, Business, News, opinion and commentary, European Union. European Commission, VLA2001 (Vaccine) -- Marketing
Abstract

Valneva announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization in Europe for Valneva's inactivated whole-virus COVID-19 vaccine candidate, VLA2001, [...]

Published
2022

25. Takeda to transfer marketing authorization for Spikevax Covid-19 vaccine in Japan to Moderna

Subjects
Moderna Inc. -- Marketing -- International economic relations, Vaccination, RNA, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda have announced the transfer of the marketing authorization for Moderna's Covid-19 vaccine Spikevax (mRNA-1273) from Takeda [...]

Published
2022

26. VBI Vaccines receives UK MHRA marketing authorization for PreHevbri

Subjects
Drug approval, Hepatitis B, Vaccines -- Marketing, Marketing, Company marketing practices, Business, News, opinion and commentary, European Union. European Commission
Abstract

VBI Vaccines announced that the UK Medicines and Healthcare Products Regulatory Agency, or MHRA, has granted marketing authorization for PreHevbri for active immunization against infection caused by all known subtypes [...]

Published
2022

27. VBI Vaccines announces EC marketing authorization for PreHevbri

Subjects
Drug approval, Hepatitis B, Vaccines -- Marketing, Marketing, Company marketing practices, Business, News, opinion and commentary, European Union. European Commission
Abstract

VBI Vaccines announced that the European Commission, or EC, has granted marketing authorization for PreHevbri or active immunisation against infection caused by all known subtypes of the hepatitis B virus, [...]

Published
2022

28. Press Release: Sanofi delivers first medicines from Global Health Unit's Impact brand portfolio

Subjects
Sanofi S.A. -- Marketing, World health, Health care reform, Insulin glargine -- Marketing, Enoxaparin -- Marketing, Vaccines -- Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Sanofi delivers first medicines from Global Health Unit's Impact brand portfolio Paris, October 19, 2023. Sanofi has delivered the first medicines from its Global Health [...]

Published
2023

29. Press Release: Sanofi delivers first medicines from Global Health Unit's Impact brand portfolio

Subjects
Sanofi S.A. -- Marketing, World health, Health care reform, Insulin glargine -- Marketing, Enoxaparin -- Marketing, Vaccines -- Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Banking, finance and accounting industries, Business
Abstract

Sanofi delivers first medicines from Global Health Unit's Impact brand portfolio Paris, October 19, 2023. Sanofi has delivered the first medicines from its Global Health Unit's not-for-profit Impact brand portfolio [...]

Published
2023

30. Novavax granted conditional marketing authorization for Nuvaxovid by Swissmedic

Subjects
Vaccines -- Marketing, Marketing, Company marketing practices, Business, News, opinion and commentary, Nuvaxovid (Vaccine) -- Marketing
Abstract

Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted Novavax conditional marketing authorization for Nuvaxovid COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in [...]

Published
2022

31. NuvaxovidTM by Novavax receives a favorable CHMP opinion for full marketing authorization in the EU for the prevention of COVID

Subjects
Novavax Inc. -- Marketing, Biotechnology industry -- Marketing, Vaccines -- Marketing, Marketing, Company marketing practices, General interest, News, opinion and commentary, European Union
Abstract

GAITHERSBURG: Novavax, Inc. has announced that NuvaxovidTM (NVX-CoV2373) has been recommended for full marketing authorization (MA) for use as a primary series in individuals aged 12 and older and as [...]

Published
2023

32. GROUNDED: Can travel retail take off post-pandemic?

Author

Wray, Julia

Subjects
Retail industry, Travel restrictions, Vaccines -- Marketing, Company marketing practices, Business, Pharmaceuticals and cosmetics industries, Business, international
Abstract

International travel restrictions have proven catastrophic for the travel retail and duty free sector. But with vaccine news spurring airline stock rebounds, Julia Wray explores what strategies to adopt as [...]

Published
2020

33. C Com Digital adopts AI-powered marketing strategies to convey diseases and disorders with empathy

Subjects
Advertising agencies, Electronic marketing, Vaccines -- Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Byline: Our Bureau C Com Digital, a full-service techno digital marketing agency with global footprint, is bringing about a paradigm shift in digital marketing approaches for the pharma sector. The [...]

Published
2021

34. Novavax's Nuvaxovid Covid-19 vaccine receives conditional marketing authorization from European Commission

Subjects
Novavax Inc. -- Marketing, Biotechnology industry -- Marketing, Drug approval, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission
Abstract

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that the European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for [...]

Published
2021

35. Moderna Covid-19 vaccine, Spikevax manufactured in Korea by Samsung Biologics gets Korean MFDS marketing authorization

Subjects
Contract manufacturing, Drug approval, RNA, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Ministry of Food and Drug Safety of Korea (MFDS) has issued a marketing authorization for Spikevax, [...]

Published
2021

36. Interview: Tata Mutual Fund Launches -- Break the Hesitancy, Max the Vax!

Subjects
Vaccination, Mutual funds -- Marketing, Vaccines -- Marketing, Company marketing practices, Personal finance
Abstract

Byline: MVS Murthy 1. An interesting campaign to break out Yes, India has just crossed a 1 billion of vaccine jabs and ' Break the Hesitancy, Max the Vax!' debuts [...]

Published
2021

37. PAR Technology's Punchh Highlights 2021 Fall Trends

Subjects
Consumer behavior, Customer loyalty, Vaccines -- Marketing, Company marketing practices, Arts and entertainment industries
Abstract

ParTech (PAR), a global restaurant technology company and provider of a unified commerce cloud platform for enterprise restaurants, and its customer loyalty, offers and engagement solution, Punchh, reported the release [...]

Published
2021

38. PAR Technology's Punchh Highlights 2021 Fall Trends

Subjects
Consumer behavior, Customer loyalty, Vaccines -- Marketing, Company marketing practices, Food and beverage industries
Abstract

ParTech (PAR), a global restaurant technology company and provider of a unified commerce cloud platform for enterprise restaurants, and its customer loyalty, offers and engagement solution, Punchh, reported the release [...]

Published
2021

39. Hilton price target raised to $154 from $145 at Argus

Subjects
Vaccines -- Marketing, Company marketing practices, Business, News, opinion and commentary
Abstract

Argus analyst John Staszak raised the firm's price target on Hilton to $154 from $145 and keeps a Buy rating on the shares. The continued rollout of COVID vaccines should [...]

Published
2021

40. Indonesia launches its first home-grown COVID-19 vaccines

Subjects
Vaccines -- Marketing, Company marketing practices, Business, international
Abstract

JAKARTA, Indonesia - Indonesia's leader launched the country's first home-grown COVID-19 shot Thursday to help reduce the world's fourth most populous nation's dependency on imported vaccines. President Joko Widodo announced [...]

Published
2022

42. Peter England launches #TimetoVaccinate campaign with special incentives

Subjects
Vaccination, Vaccines -- Marketing, Company marketing practices, Advertising, marketing and public relations
Abstract

Peter England, a leading international menswear brand from Aditya Birla Fashion and Retail Limited, has launched a unique initiative #TimetoVaccinate, to encourage the ongoing vaccination drive in the country. The [...]

Published
2021

43. How marketing & communication in Real Estate undergone transformation

Subjects
Vaccines -- Marketing, Marketing, Real property -- Marketing, Company marketing practices, Advertising, marketing and public relations
Abstract

Byline: Piali Dasgupta It is no secret that COVID-19 has majorly transformed the marketing landscape across the world in the past 14 months. It has been the real accelerator to [...]

Published
2021

44. Peloton price target lowered to $120 from $180 at Argus

Subjects
Vaccines -- Marketing, Company marketing practices, Business, News, opinion and commentary
Abstract

Argus analyst John Staszak lowered the firm's price target on Peloton to $120 from $180 but keeps a Buy rating on the shares. The company has seen strong demand during [...]

Published
2021

45. CVS Health price target raised to $98 from $82 at Mizuho

Subjects
CVS Health Corp. -- Marketing, Drugstores -- Marketing, Vaccines -- Marketing, Company marketing practices, Business, News, opinion and commentary
Abstract

Mizuho analyst Ann Hynes raised the firm's price target on CVS Health to $98 from $82 and keeps a Buy rating on the shares. The analyst continues to expect the [...]

Published
2021

47. Brokerage Barclays sets price target to GBX 1,450 for GSK

Subjects
Vaccines -- Marketing, Company marketing practices, General interest, News, opinion and commentary
Abstract

The latest price target for GSK (LON:GSK) was reported by Barclays. Barclays's analyst Emily Field has assigned a price target of GBX 1,450 for GSK. The stock current price is [...]

Published
2023

48. Barclays sets price target to GBX 1,450 for GSK

Subjects
Vaccines -- Marketing, Company marketing practices, General interest, News, opinion and commentary
Abstract

The latest price target for GSK (LON:GSK) was reported by Barclays. Barclays's analyst Emily Field has assigned a price target of GBX 1,450 for GSK. The stock current price is [...]

Published
2023

49. Analyst firm Jefferies Financial Group sets price target to GBX 1,575 for GSK

Subjects
Jefferies Financial Group Inc. -- Marketing, Financial analysts, Financial services industry -- Marketing, Vaccines -- Marketing, Company marketing practices, Financial services industry, General interest, News, opinion and commentary
Abstract

The latest price target for GSK (LON:GSK) was reported by Jefferies Financial Group. Jefferies Financial Group's analyst Peter Welford has assigned a price target of GBX 1,575 for GSK. The [...]

Published
2023

50. Barclays assigns price target to GBX 1,450 for GSK

Subjects
Vaccines -- Marketing, Company marketing practices, General interest, News, opinion and commentary
Abstract

The latest price target for GSK (LON:GSK) was reported by Barclays. Barclays's analyst Emily Field has assigned a price target of GBX 1,450 for GSK. The stock current price is [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results